PDCD11 and cancer: To investigate the role of PDCD11 overexpression in representative p53‐mutant cancer cases, we performed Kaplan‐Meier survival analyses.[13] High‐level PDCD11 shortened the overall survival (OS), recurrence‐free survival (RFS), and distant metastasis‐free survival (DMFS) in patients with p53‐mutant breast cancer with lymph node positivity within 5 years (Figure 1C–E), as well as the 5‐year OS and RFS of p53‐mutant colon cancer patients (Stage T1‐T3) (Figure 1F,G), revealing that PDCD11 abundance is closely and positively correlated.